Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065758 | 0.80 | HTR2C (0.77) | HTR2CHTR2AHTR2BDRD2HTR1A | |
| SCHEMBL16457233 | 0.77 | HTR2C (0.72) | HTR2CHTR2AHTR2BDRD2HTR1A | |
| SCHEMBL2532290 | 0.77 | HTR2C (0.72) | HTR2CHTR2AHTR2BDRD2HTR1A | |
| SCHEMBL25121942 | 0.76 | HTR2C (0.56) | HTR2CHTR2AHTR2BDRD2HTR1A | |
| SCHEMBL5668848 | 0.76 | HTR2C (0.70) | HTR2CHTR2AHTR2BDRD2 | |
| Cyanide SCHEMBL27792102 | 0.76 | HTR2C (0.70) | HTR2CHTR2AHTR2BDRD2HTR1A | |
| SCHEMBL31087548 | 0.76 | HTR2C (0.70) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL29991200 | 0.75 | HTR2C (0.52) | HTR2CKDM1ARCOR1TSHR | |
| SCHEMBL27343752 | 0.74 | HTR2C (0.54) | HTR2CHTR2AHTR2BDRD2HTR1A | |
| SCHEMBL4068122 | 0.74 | HTR2C (0.68) | HTR2CHTR2AHTR2BDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HTR2C 1817/4885HTR2A 2475/4885HTR2B 1286/4885 |
| US-20220363651-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HTR2C 1817/4885HTR2A 2475/4885HTR2B 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.